None listed
Conditions
Brief summary
The Brien Holden Vision Institute (previously known as the Institute for Eye Research) conducted a clinical trial to test commercially-available multifocal contact lenses for their potential to control the progression of myopia in children(IERP2007-009, ACTRN12611001148965). The trial was completed in 2008. Approximately half of the 40 children who participated in trial IERP2007-009 were enrolled in a subsequent myopia control trial at the Brien Holden Vision Institute (IER2008-001, ACTRN12611001141932) in which all participants wore the test product of trial IERP2007-009. This research is based on the hypothesis that the peripheral retina plays a role in controlling the refractive development of the eye as shown in animal experiments (Smith et al. 2007).
Interventions
Cycloplegic refractive error will be measured both objectively and subjectively; ocular axial length will be measured using a Zeiss IOL master. Cycloplegia will be achieved using diagnostic eye drops (1% tropicamide and 0.4% oxybuprocaine).
Sponsors
Brien Holden Vision Institute
Eligibility
Sex/Gender
All
Age
15 Years to 21 Years
Healthy volunteers
Yes
Inclusion criteria
have successfully enrolled in study IERP2007-009 be able to read and comprehend English and give informed consent as demonstrated by signing a record of informed consent (or their parent(s)/legal guardian); if under 18 years of age, be accompanied by their parent(s)/legal guardian when signing the informed consent form; be willing to comply with the clinical trial visit schedule as directed by the investigator; have ocular health findings considered to be “normal”;
Exclusion criteria
Any pre-existing ocular irritation, injury or condition (including infection or disease) of the cornea, conjunctiva or eyelids that would preclude the use of diagnostic eye drops (1% tropicamide and 0.4% oxybuprocaine). a need for concurrent category S3 and above ocular medication up to 12 weeks prior to and during the trial; any systemic disease that may affect ocular health. Conditions such as systemic hypertension do not automatically exclude prospective participants; any systemic or topical medications up to 12 weeks prior to and during the trial that will affect ocular physiology; had eye surgery within 12 weeks immediately prior to enrolment for this trial; known allergy or intolerance to ingredients in any of the clinical trial products
Outcome results
None listed